# Pharma Power: L'Architettura del Potere Sanitario Globale

> Come fondazioni private, PPP, revolving door FDA e network forum hanno ridisegnato la governance sanitaria mondiale

## Executive Summary

Questo report analizza il **network di potere nell'industria farmaceutica e nella salute globale**, identificando:

| Cluster | Entità Chiave | Pattern |
|---------|---------------|---------|
| **Fondazioni** | Gates Foundation ($77B), Wellcome Trust ($38B) | Funding → Influence |
| **PPP (Public-Private Partnership)** | GAVI, CEPI, Global Fund | Governance parallela |
| **WHO** | $6.8B budget, 83% voluntary | Donor capture |
| **Big Pharma** | Pfizer, J&J, Roche, Novartis, Moderna, BioNTech, AstraZeneca, Merck, GSK, **Eli Lilly ($1T)** | Oligopolio, revolving door |
| **Regolatori** | FDA (65% industry-funded) | Regulatory capture |
| **Forum** | WEF (Hoffmann Co-Chair), PhRMA, CFR (Glocer) | Industry coordination |

**Tesi**: La salute globale post-2000 è governata da un sistema parallelo di PPP dominate da fondazioni private (Gates) e pharma, con WHO ridotta a dipendenza da donatori volontari, regolatori catturati dall'industria, e forum globali (WEF) con leadership diretta da Big Pharma (Hoffmann/Roche).

---

## Mappa del Network (Aggiornata)

```
                         GLOBAL HEALTH GOVERNANCE
                                  │
         ┌────────────────────────┼────────────────────────┐
         │                        │                        │
         ▼                        ▼                        ▼
   ┌───────────┐            ┌───────────┐            ┌───────────┐
   │ FONDAZIONI│            │    PPP    │            │  FORUM    │
   │  PRIVATE  │            │           │            │  GLOBALI  │
   └─────┬─────┘            └─────┬─────┘            └─────┬─────┘
         │                        │                        │
    ┌────┴────┐              ┌────┴────┐              ┌────┴────┐
    │         │              │         │              │         │
    ▼         ▼              ▼         ▼              ▼         ▼
┌───────┐ ┌───────┐      ┌──────┐ ┌──────┐      ┌──────┐ ┌──────┐
│ GATES │ │WELLCOME│     │ GAVI │ │ CEPI │      │ WEF  │ │PhRMA │
│ $77B  │ │ $38B  │      │      │ │      │      │      │ │      │
└───┬───┘ └───┬───┘      └───┬──┘ └───┬──┘      └───┬──┘ └───┬──┘
    │         │              │        │              │        │
    └────┬────┴──────────────┴────────┘              │        │
         │                                           │        │
         ▼                                           │        │
   ┌───────────┐                              ┌──────┴────────┴──────┐
   │    WHO    │◄────── Revolving Door ──────►│      BIG PHARMA      │
   │  (donor   │                              │                      │
   │  captured)│                              │ Pfizer  J&J  Moderna │
   └───────────┘                              │ Roche Novartis Merck │
         │                                    │ BioNTech AZ GSK      │
         │                                    └──────────┬───────────┘
         │                                               │
         └───────────────────────────────────────────────┘
                                │
                                ▼
                          ┌───────────┐
                          │    FDA    │
                          │   (65%    │
                          │ industry  │
                          │  funded)  │
                          └───────────┘
```

---

## 1. Gates Foundation: L'Architetto

### Profilo

| Metrica | Valore |
|---------|--------|
| **Endowment** | $77.2B (2024) |
| **Grant totali** | $83.3B dal 2000 |
| **Budget annuale** | ~$9B |
| **Chairman** | Bill Gates |
| **CEO** | Mark Suzman |
| **Sunset** | 2045 (chiusura annunciata) |

### Funding Network

```
GATES FOUNDATION ($77B)
        │
        ├──► WHO (~$830M/anno, ~10% budget, 2nd funder)
        │
        ├──► GAVI ($4.1B totali, ~20% budget, board seat)
        │
        ├──► CEPI (co-founder 2017)
        │
        ├──► BioNTech ($55M, 2019, HIV/TB programs)
        │
        └──► Global Fund ($2.5B+)
```

**Scheda**: [Gates Foundation](../docs/foundation/gates-foundation.md)

---

## 2. GAVI e CEPI: Il Modello PPP

### GAVI: Il Caso Barroso

```
JOSÉ MANUEL BARROSO
        │
        ├── 1993: GLT (Global Leader for Tomorrow) WEF
        ├── 2002-2004: PM Portogallo
        ├── 2004-2014: Presidente Commissione Europea
        ├── 2016-oggi: Chairman Goldman Sachs International
        └── 2021-oggi: Chairman GAVI
```

**Pattern**: Barroso è simultaneamente Chairman Goldman Sachs E Chairman GAVI.

**Scheda**: [GAVI](../docs/agency/gavi.md)

### CEPI: Nato a Davos

| Metrica | Valore |
|---------|--------|
| **Fondazione** | 2017 (WEF Davos) |
| **CEO** | Richard Hatchett (ex-BARDA, NSC, HSC) |
| **Funding totale** | $3.1B |

**Scheda**: [CEPI](../docs/agency/cepi.md)

---

## 3. WHO: Donor Capture

### Il Problema Strutturale

| Metrica | Valore |
|---------|--------|
| **Budget 2024-25** | $6.83B |
| **Voluntary contributions** | **83%** |
| **Assessed contributions** | 17% |

**Implicazione**: Chi paga di più (USA, Germania, Gates) controlla l'agenda.

**Scheda**: [WHO](../docs/agency/who.md)

---

## 4. Big Pharma: Profiles Completi

### Overview

| Azienda | HQ | Revenue 2024 | CEO | Pattern Chiave |
|---------|-----|--------------|-----|----------------|
| [Pfizer](../docs/pharma/pfizer.md) | USA | $63.6B | Albert Bourla | Gottlieb (ex-FDA) in board |
| **[Eli Lilly](../docs/pharma/eli-lilly.md)** | USA | **$63B** | **David Ricks** | **$1T market cap** (Nov 2025), ex-PhRMA Chair, Nobel (Kaelin) in board |
| [J&J](../docs/pharma/johnson-johnson.md) | USA | $88.8B | Joaquin Duato | McClellan (ex-FDA) in board |
| [Moderna](../docs/pharma/moderna.md) | USA | $3.2B | Stephane Bancel | Hahn (ex-FDA) → Flagship, Rubenstein (CFR) in board |
| [BioNTech](../docs/pharma/biontech.md) | DEU | - | Ugur Sahin | Strungmann twins control (~50%) |
| [Roche](../docs/pharma/roche.md) | CHE | $68.7B | Thomas Schinecker | **Hoffmann WEF Co-Chair** |
| [Novartis](../docs/pharma/novartis.md) | CHE | $51.7B | Vas Narasimhan | **PhRMA Chair** |
| [AstraZeneca](../docs/pharma/astrazeneca.md) | UK | $45.8B | Pascal Soriot | **Henney (ex-FDA)** in board, WEF |
| [Merck](../docs/pharma/merck.md) | USA | $64.2B | Robert Davis | **Glocer (CFR, Morgan Stanley)**, Warden (Northrop) |
| [GSK](../docs/pharma/gsk.md) | UK | £31.4B | Emma Walmsley | **Microsoft board**, Symonds (ex-CFO Novartis+AZ) |

### Basel Pharma Hub

```
BASEL, SWITZERLAND
        │
        ├── ROCHE ($68.7B)
        │       └── Hoffmann family control (50%)
        │       └── Andre Hoffmann = WEF Co-Chair
        │
        └── NOVARTIS ($51.7B)
                └── Narasimhan = PhRMA Chair

        TOTAL: $120B revenue in una città
```

---

## 5. FDA Revolving Door: Pattern Completo

### I 4 Vaccini COVID Principali

```
VACCINO COVID         EX-FDA COMMISSIONER         DESTINAZIONE

    Pfizer       ───►  Scott Gottlieb (2017-19)  ───►  Board Pfizer
                                                       (83 giorni dopo)

    J&J          ───►  Mark McClellan (2002-04)  ───►  Board J&J
                                                       (dal 2013)

    Moderna      ───►  Stephen Hahn (2019-21)    ───►  Flagship Pioneering
                                                       (incubatore Moderna)

    AstraZeneca  ───►  Jane Henney (1999-01)     ───►  Board AstraZeneca
                                                       (prima donna FDA)
```

**Pattern**: Tutte e 4 le aziende con vaccini COVID approvati hanno ex-FDA Commissioner nei rispettivi board/incubatori.

### FDA Funding Model

| Fonte | % Budget |
|-------|----------|
| **Industry user fees** | **65%** |
| Governo federale | 35% |

> "When your No. 1 major employer after you leave is sitting across the table, you're not going to be a hard-ass when you regulate." - Vinay Prasad, M.D.

### Commissioners Post-2000: Tutti in Industria

| Commissioner | Mandato | Dopo FDA | Scheda |
|--------------|---------|----------|--------|
| **Jane Henney** | 1999-01 | **AstraZeneca board** (prima donna FDA) | Stub |
| Mark McClellan | 2002-04 | J&J board | Stub |
| Andrew von Eschenbach | 2006-09 | BioTime, Viamet boards | - |
| **[Margaret Hamburg](../docs/persons/margaret-hamburg.md)** | 2009-15 | Alnylam, **GAVI, CEPI, CFR, Gates, NTI** | **✅** |
| **[Scott Gottlieb](../docs/persons/scott-gottlieb.md)** | 2017-19 | Pfizer board (**83 giorni**), Illumina Chairman, AEI, NEA | **✅** |
| Stephen Hahn | 2019-21 | Flagship Pioneering (Moderna) | Stub |
| Robert Califf | 2016-17, 2022- | Verily (Alphabet) $2.7M | - |

### Il Caso Hamburg: Network Completo

**[Margaret Hamburg](../docs/persons/margaret-hamburg.md)** e' l'unico ex-FDA Commissioner a entrare simultaneamente in:

```
FDA COMMISSIONER (2009-2015)
         │
         ├──► PPP: GAVI board, CEPI board
         │
         ├──► FONDAZIONI: Gates (advisor), Rockefeller (ex-board)
         │
         ├──► THINK TANK: CFR board, CSIS
         │
         ├──► PHARMA: Alnylam board
         │
         ├──► BIOSECURITY: NTI (Chair bio Advisory Group)
         │
         └──► INTELLIGENCE: Vice Chair PIAB, ex-CIA Science Board
```

**Pattern unico**: Hamburg collega regolatore, PPP globali, fondazioni, think tank, pharma E intelligence.

### FDA → Big Pharma COVID Vaccines (Completo)

| Vaccino | Ex-FDA Commissioner | Destinazione |
|---------|---------------------|--------------|
| Pfizer | [Scott Gottlieb](../docs/persons/scott-gottlieb.md) (2017-19) | Pfizer board (83 giorni) |
| J&J | Mark McClellan (2002-04) | J&J board (dal 2013) |
| Moderna | Stephen Hahn (2019-21) | Flagship Pioneering (incubatore) |
| **AstraZeneca** | **Jane Henney (1999-01)** | **AstraZeneca board** |

**Pattern**: 4 su 4 vaccini COVID principali hanno ex-FDA Commissioner nei rispettivi board.

**Scheda**: [FDA](../docs/agency/fda.md)

---

## 6. WEF: Pharma al Vertice

### Leadership WEF 2025

| Data | Evento |
|------|--------|
| **Apr 2025** | Klaus Schwab lascia WEF board |
| **Apr 2025** | Peter Brabeck-Letmathe interim chairman |
| **15 Ago 2025** | **Hoffmann + Fink nominati Co-Chairs** |

| Ruolo | Nome | Background | Net Worth |
|-------|------|------------|-----------|
| **Co-Chair** | [Larry Fink](../docs/persons/larry-fink.md) | CEO BlackRock | - |
| **Co-Chair** | **[Andre Hoffmann](../docs/persons/andre-hoffmann.md)** | Vice-Chairman **Roche** (5a gen) | **$9.38B** |

**Pattern**: Il forum globale piu' influente e' co-guidato dal CEO del piu' grande asset manager E dall'erede della dinastia farmaceutica svizzera.

### [Andre Hoffmann](../docs/persons/andre-hoffmann.md): Il Ponte Pharma-WEF-Environment

```
ANDRE HOFFMANN ($9.38B)
        │
        ├── PHARMA
        │       ├── Vice-Chairman Roche (5a generazione, dal 2006)
        │       ├── Board Genentech
        │       └── Famiglia controlla ~50% voting Roche
        │
        ├── WEF: Co-Chair (con Larry Fink, dal 15 Ago 2025)
        │
        ├── ENVIRONMENT
        │       ├── Ex-VP WWF International (2007-2017, 10 anni)
        │       ├── President MAVA Foundation
        │       ├── President Tour du Valat
        │       └── Padre Luc Hoffmann = co-fondatore WWF (1961)
        │
        └── FORUM/THINK TANKS
                ├── Club of Rome (member)
                ├── INSEAD Hoffmann Institute (Chairman)
                └── SystemIQ (board)
```

**Implicazione**: Hoffmann incarna il "stakeholder capitalism" - pharma + environment + global governance in una persona.

---

## 7. PhRMA: La Lobby

**Scheda**: [PhRMA](../docs/agency/phrma.md) **✅**

### Profilo

| Metrica | Valore |
|---------|--------|
| **Fondazione** | 1958 |
| **Sede** | Washington DC, USA |
| **Revenue** | $455M (2017) |
| **Lobbying 2024** | **$31.7M** (record) |
| **Lobbying 2025 H1** | $20.6M (on pace $450M+ industria) |
| **President & CEO** | Stephen Ubl (2015-) |

### Chair Rotation

| Anno | PhRMA Chair | Azienda | Scheda |
|------|-------------|---------|--------|
| 2020-22 | **[David Ricks](../docs/persons/david-ricks.md)** | **Eli Lilly** | Stub |
| 2022-23 | **[Albert Bourla](../docs/persons/albert-bourla.md)** | Pfizer | **✅** |
| 2023-24 | **Vas Narasimhan** | **Novartis** | Stub |
| 2024- | **Daniel O'Day** | **Gilead** | Stub |

**Pattern**: I CEO delle Big Pharma si alternano come Chair della lobby USA.

### Il Caso Billy Tauzin: Revolving Door Emblematico

```
CONGRESSMAN (1980-2004)
   Chair House Energy & Commerce Committee
         │
         ▼
MEDICARE PART D (2003)
   Scrisse legge che VIETA negoziazione prezzi Medicare
         │
         ▼ (2 mesi dopo lascia Congresso)
PhRMA PRESIDENT (2005-2010)
   Salary: $2M/anno → $11.6M (2010)
```

**Pattern**: Tauzin scrisse legge favorevole a pharma (divieto negoziazione prezzi 19 anni), poi assunto da pharma con stipendio record.

### Member Exits Post-IRA (2022-2023)

| Azienda | Exit | Impatto |
|---------|------|---------|
| AbbVie | Dic 2022 | - |
| Teva | Feb 2023 | - |
| AstraZeneca | Mag 2023 | - |
| **Totale** | - | **-$100M dues/anno** |

**Contesto**: Dopo approvazione Inflation Reduction Act (prima negoziazione prezzi Medicare), 3 major companies lasciano PhRMA.

### [Albert Bourla](../docs/persons/albert-bourla.md): Profilo

| Dato | Dettaglio |
|------|-----------|
| **Origine** | Thessaloniki, Grecia (ebreo sefardita) |
| **Genitori** | Sopravvissuti Olocausto |
| **Formazione** | Veterinario, PhD Biotechnology |
| **In Pfizer dal** | 1993 (30+ anni) |
| **CEO Pfizer** | 2019 |
| **Chairman Pfizer** | 2020 |

**Altri ruoli Bourla**:
- Chairman PhRMA (lobby pharma USA)
- Ex-President IFPMA (lobby pharma global)
- Member Business Roundtable
- Member Business Council
- Co-Chair Partnership for NYC
- WEF Agenda Contributor

**Pattern**: "Company man" (carriera interna 30 anni) + voce principale industria pharma (PhRMA + IFPMA).

---

## 8. Nuovi Pattern: CFR, Defense, Tech

### CFR-Wall Street-Pharma Triangle (Merck)

```
THOMAS GLOCER
    │
    ├── MERCK (Lead Director)
    │       └── $64B pharma
    │
    ├── MORGAN STANLEY (Lead Director)
    │       └── $177B bank
    │
    └── CFR (Member)
            └── Foreign policy establishment
```

**Pattern**: Glocer collega simultaneamente Big Pharma, Wall Street e foreign policy.

### Defense-Pharma Crosslink (Merck)

```
KATHY WARDEN
    │
    ├── NORTHROP GRUMMAN (CEO/Chairman)
    │       └── 5° contractor difesa USA ($41B)
    │
    └── MERCK (Board)
            └── 4° pharma USA ($64B)
```

**Pattern**: CEO del 5° contractor difesa siede nel board del 4° pharma.

### Tech-Pharma Board Crossover (GSK)

```
EMMA WALMSLEY
    │
    ├── GSK (CEO)
    │       └── £31B pharma
    │
    └── MICROSOFT (Board)
            └── Big Tech + healthcare AI
```

**Pattern**: CEO Big Pharma (prima donna) siede in board Big Tech.

### Executive Rotation Pharma (GSK)

```
JONATHAN SYMONDS (GSK Chairman)
    │
    ├── AstraZeneca (ex-CFO)
    │
    ├── Novartis (ex-CFO)
    │
    └── GSK (Chairman)

LUKE MIELS (GSK incoming CEO)
    │
    ├── AstraZeneca (ex)
    ├── Roche (ex)
    ├── Sanofi (ex)
    └── GSK (CEO 2026)
```

**Pattern**: Il settore pharma e' un club chiuso con executive che ruotano tra le stesse 6-7 aziende.

---

## 9. Moderna: Il Caso Estremo

### Network Connections

```
MODERNA
    │
    ├── FLAGSHIP PIONEERING (incubatore)
    │       ├── Noubar Afeyan (CEO Flagship, Chairman Moderna)
    │       └── Stephen Hahn (ex-FDA Commissioner → CMO Flagship)
    │
    ├── BOARD CONNECTIONS
    │       └── DAVID RUBENSTEIN
    │               ├── Co-founder Carlyle Group
    │               ├── Chairman CFR
    │               ├── Bilderberg member
    │               ├── Trilateral member
    │               └── WEF board
    │
    ├── GOVERNMENT FUNDING
    │       ├── DARPA ($25M, 2013)
    │       ├── BARDA ($955M)
    │       └── Totale: ~$6B pubblici
    │
    └── NIH CO-OWNERSHIP
            └── Patent vaccino co-owned da NIH
```

**Pattern**: Moderna collega DARPA, venture capital, ex-FDA, CFR/Bilderberg/Trilateral (via Rubenstein), e funding pubblico massiccio.

**Scheda**: [Moderna](../docs/pharma/moderna.md)

---

## 10. Harvard Medical School: Network Hub Accademico

**Scheda**: [Harvard Medical School](../docs/company/harvard-medical-school.md) **✅**

### Board of Fellows come Hub

Il Board of Fellows (creato 1990) e' un advisory board non-fiduciario che connette pharma, biotech e accademia:

```
HMS BOARD OF FELLOWS
        │
        ├── CHAIRMAN: Ernesto Bertarelli
        │       ├── Ex-CEO Serono (venduta $13.3B)
        │       ├── B-Flexion family office
        │       └── HBS Dean's Advisors
        │
        ├── Vas Narasimhan
        │       ├── CEO Novartis
        │       └── PhRMA Chair 2023-24
        │
        ├── William Kaelin (Nobel 2019)
        │       └── Eli Lilly board
        │
        └── Michael Rosenblatt (2025)
                ├── Ex-CMO Merck
                └── Flagship Pioneering advisor
```

### [Ernesto Bertarelli](../docs/persons/ernesto-bertarelli.md): Ponte Swiss-Harvard

**Scheda**: **✅**

| Dato | Dettaglio |
|------|-----------|
| **Net Worth** | $11.58B |
| **Famiglia** | [Bertarelli](../docs/family/bertarelli.md) (3a gen pharma) |
| **Exit** | Serono → Merck KGaA ($13.3B, 2007) |
| **Family Office** | [B-Flexion](../docs/private-equity/b-flexion.md) |
| **Donazione HMS** | $75M (2023) |

```
ERNESTO BERTARELLI ($11.58B)
        │
        ├── HARVARD
        │       ├── HMS Board of Fellows (Chairman)
        │       ├── HBS Dean's Advisors
        │       └── $75M donation (2023)
        │
        ├── SVIZZERA
        │       ├── Campus Biotech Geneva (co-founder)
        │       ├── EPFL Advisory Board
        │       └── UBS board (2002-09)
        │
        └── INVESTIMENTI
                ├── B-Flexion (chairman)
                └── Bertarelli Foundation (co-chair)
```

**Pattern**: Bertarelli connette Harvard (HMS + HBS), Svizzera (EPFL, Campus Biotech), e filantropia (fondazione), creando un ponte Swiss-American nel settore life sciences.

### Caso Elizabeth Holmes (2015-2016)

| Data | Evento |
|------|--------|
| 2015 | Jeffrey Flier (Dean) invita Holmes al Board of Fellows |
| 2015 | Wall Street Journal pubblica expose' Theranos |
| 2016 | Holmes chiede dimissioni |
| 2022 | Holmes condannata per frode |

**Lezione**: Mancanza di due diligence nell'ammissione al Board of Fellows.

---

## 11. Eli Lilly: Il Primo Trilione

**Scheda**: [Eli Lilly](../docs/pharma/eli-lilly.md) **✅**

### $1 Trillion Milestone (Nov 2025)

| Metrica | Valore |
|---------|--------|
| **Market Cap** | **$1 trillion** (primo healthcare) |
| **Revenue 2025** | ~$63B |
| **GLP-1 Share** | 53% globale (sorpasso Novo Nordisk) |
| **Chairman & CEO** | [David Ricks](../docs/persons/david-ricks.md) (2017-) |

### Crescita sotto Ricks

```
2017: Ricks CEO (~$70B market cap)
      │
      ▼
2022: Mounjaro (tirzepatide) approval
      │
      ▼
2023: Zepbound (obesity) approval
      │
      ▼
Nov 2025: $1 TRILLION (14x in 8 anni)
```

### Network CEO

```
DAVID RICKS
    │
    ├── Eli Lilly (Chairman & CEO 2017-)
    │
    ├── PhRMA (Board Chair 2020-22)
    │
    ├── Business Roundtable (member)
    │
    └── Adobe (board)
```

### Lilly Endowment

| Metrica | Valore |
|---------|--------|
| **Assets** | **$80B** (2024) |
| **Fondazione** | 1937 (famiglia Lilly) |
| **Focus** | Indiana, Religion, Education |
| **Relazione** | Entita' separata da azienda |

**Pattern**: Famiglia Lilly uscita dalla gestione operativa (Gen 4), ma influenza mantenuta attraverso Lilly Endowment ($80B), una delle piu' grandi fondazioni USA.

---

## 12. Pattern Identificati

### 1. Regulatory Capture Sistemica

```
FDA (65% industry-funded)
        │
        ├── 9/10 Commissioners → industria
        │
        ├── User fees = industry pays for review
        │
        └── "Behind the scenes" lobbying permesso
```

### 2. Forum come Governance Parallela

| Forum | Ruolo Pharma |
|-------|--------------|
| **WEF** | [Andre Hoffmann](../docs/persons/andre-hoffmann.md) (Roche) Co-Chair dal Ago 2025 |
| **PhRMA** | CEO rotation ([Bourla](../docs/persons/albert-bourla.md) → Narasimhan → Schinecker) |
| **CFR** | [Margaret Hamburg](../docs/persons/margaret-hamburg.md) board, Rubenstein Chairman |
| **Bilderberg** | Rubenstein (Moderna board) |
| **Club of Rome** | [Andre Hoffmann](../docs/persons/andre-hoffmann.md) member |
| **NTI** | [Margaret Hamburg](../docs/persons/margaret-hamburg.md) Chair bio Advisory |

### 2b. Pattern Hamburg: Regolatore → Full Network

[Margaret Hamburg](../docs/persons/margaret-hamburg.md) rappresenta il pattern piu' completo di revolving door:

| Settore | Posizione |
|---------|-----------|
| **Regolatore** | FDA Commissioner 2009-15 |
| **PPP** | GAVI board, CEPI board |
| **Fondazioni** | Gates advisor, Rockefeller ex-board |
| **Think Tank** | CFR board, CSIS |
| **Pharma** | Alnylam board |
| **Biosecurity** | NTI Chair bio Advisory |
| **Intelligence** | Vice Chair PIAB, ex-CIA Science Board |

**Differenza da altri ex-FDA**: Gottlieb, Hahn, McClellan vanno "solo" in pharma/VC. Hamburg entra in tutto il network.

### 3. PPP Bypass Accountability

```
GOVERNI ──► ONU/WHO ──► Accountability statale

vs.

GATES + PHARMA ──► GAVI/CEPI ──► Accountability donatori
```

### 4. Asset Manager Governance

```
BIG THREE (Vanguard, BlackRock, State Street)
        │
        ├── Top shareholders tutte Big Pharma
        │
        ├── Tim Buckley (ex-CEO Vanguard) → Pfizer board
        │
        ├── Cyrus Taraporevala (ex-CEO SSGA) → Pfizer board
        │
        └── Larry Fink (BlackRock) = WEF Co-Chair con Hoffmann (Roche)
```

### 5. Revolving Door Multilaterale

| Da | A | Esempio |
|----|---|---------|
| FDA Commissioner | Pharma board | Gottlieb → Pfizer |
| EU Commission President | Pharma PPP + Goldman | Barroso → GAVI + GS |
| US Security Council | Global Health PPP | Hatchett → CEPI |
| FDA Commissioner | Pharma incubator | Hahn → Flagship |

---

## 13. Entità nel Database

### Organizzazioni (Schede Complete)

| ID | Tipo | Scheda |
|----|------|--------|
| [gates-foundation](../docs/foundation/gates-foundation.md) | Foundation | ✅ |
| [gavi](../docs/agency/gavi.md) | Agency | ✅ |
| [who](../docs/agency/who.md) | Agency | ✅ |
| [cepi](../docs/agency/cepi.md) | Agency | ✅ |
| [fda](../docs/agency/fda.md) | Agency | ✅ |
| **[phrma](../docs/agency/phrma.md)** | Agency | **✅** |
| [pfizer](../docs/pharma/pfizer.md) | Pharma | ✅ |
| **[eli-lilly](../docs/pharma/eli-lilly.md)** | Pharma | **✅** |
| [johnson-johnson](../docs/pharma/johnson-johnson.md) | Pharma | ✅ |
| [moderna](../docs/pharma/moderna.md) | Pharma | ✅ |
| [biontech](../docs/pharma/biontech.md) | Pharma | ✅ |
| [roche](../docs/pharma/roche.md) | Pharma | ✅ |
| [novartis](../docs/pharma/novartis.md) | Pharma | ✅ |
| [flagship-pioneering](../docs/private-equity/flagship-pioneering.md) | PrivateEquity | Stub |
| **[b-flexion](../docs/private-equity/b-flexion.md)** | PrivateEquity | Stub |
| [astrazeneca](../docs/pharma/astrazeneca.md) | Pharma | ✅ |
| [merck](../docs/pharma/merck.md) | Pharma | ✅ |
| [gsk](../docs/pharma/gsk.md) | Pharma | ✅ |
| **[harvard-medical-school](../docs/company/harvard-medical-school.md)** | University | **✅** |
| [morgan-stanley](../docs/bank/morgan-stanley.md) | Bank | Stub |
| [northrop-grumman](../docs/company/northrop-grumman.md) | Company | Stub |
| [microsoft](../docs/company/microsoft.md) | Company | Stub |
| **[lilly-endowment](../docs/foundation/lilly-endowment.md)** | Foundation | Stub |

### Persone Chiave

| ID | Ruolo | Scheda |
|----|-------|--------|
| **[albert-bourla](../docs/persons/albert-bourla.md)** | CEO Pfizer, Chairman PhRMA | **✅** |
| **[scott-gottlieb](../docs/persons/scott-gottlieb.md)** | Ex-FDA → Pfizer (83 giorni), Illumina Chairman | **✅** |
| **[margaret-hamburg](../docs/persons/margaret-hamburg.md)** | Ex-FDA → GAVI, CEPI, CFR, Gates, NTI, Alnylam | **✅** |
| **[andre-hoffmann](../docs/persons/andre-hoffmann.md)** | Roche Vice-Chair, **WEF Co-Chair** | **✅** |
| **[ernesto-bertarelli](../docs/persons/ernesto-bertarelli.md)** | HMS Board Chair, ex-CEO Serono, B-Flexion | **✅** |
| **[david-ricks](../docs/persons/david-ricks.md)** | CEO Eli Lilly, ex-PhRMA Chair | Stub |
| joaquin-duato | CEO J&J | Stub |
| mark-mcclellan | Ex-FDA → J&J | Stub |
| stephane-bancel | CEO Moderna | Stub |
| stephen-hahn | Ex-FDA → Flagship | Stub |
| noubar-afeyan | Flagship/Moderna | Stub |
| billy-tauzin | **Ex-Congressman → PhRMA ($2M/anno)** | Stub |
| daniel-oday | CEO Gilead, **PhRMA Chair 2024** | Stub |
| [david-rubenstein](../docs/persons/david-rubenstein.md) | Moderna board, CFR Chair | Esistente |
| ugur-sahin | CEO BioNTech | Stub |
| ozlem-tureci | CMO BioNTech | Stub |
| thomas-schinecker | CEO Roche | Stub |
| [vas-narasimhan](../docs/persons/vas-narasimhan.md) | CEO Novartis, **PhRMA Chair**, HMS Board | Esistente |
| [jose-barroso](../docs/persons/jose-barroso.md) | GAVI Chair, Goldman | Esistente |
| pascal-soriot | CEO AstraZeneca, WEF | Stub |
| jane-henney | **Ex-FDA → AstraZeneca** | Stub |
| michel-demare | Chairman AstraZeneca | Stub |
| robert-davis | CEO/Chairman Merck | Stub |
| **[thomas-glocer](../docs/persons/thomas-glocer.md)** | **Lead Director Merck + Morgan Stanley, CFR**, ex-CEO Thomson Reuters | **✅** |
| **[kathy-warden](../docs/persons/kathy-warden.md)** | **CEO Northrop Grumman → Merck board** | **✅** |
| emma-walmsley | CEO GSK, **Microsoft board** | Stub |
| jonathan-symonds | Chairman GSK, ex-CFO Novartis+AZ | Stub |
| luke-miels | Incoming CEO GSK | Stub |
| william-kaelin | **Nobel 2019, HMS Prof, Eli Lilly board** | Stub |

---

## 14. Implicazioni

### 1. Unelected Power

| Posizione | Accountability |
|-----------|----------------|
| WEF Co-Chair (Hoffmann, Fink) | Nessuna elettorale |
| PhRMA Chair (Narasimhan) | Solo shareholders |
| Gates Foundation | Fondazione privata |
| GAVI/CEPI | Donatori |

### 2. Circolarità Governance

```
PHARMA CEO ──► PhRMA Chair ──► Lobbying ──► FDA policy
     │                                          │
     └──────────────────────────────────────────┘
                         │
                    FDA Commissioner
                         │
                         ▼
                    Pharma Board
```

### 3. Public Money, Private Control

| Entità | Funding Pubblico | Controllo |
|--------|------------------|-----------|
| Moderna | ~$6B USA | Flagship, shareholders |
| BioNTech | CEPI $145M | Strungmann twins |
| J&J vaccine | BARDA $1B+ | J&J shareholders |

---

## 15. Domande Aperte

1. **WEF post-Schwab**: Hoffmann + Fink consolidano pharma + finance al vertice?
2. **Gates Foundation 2045**: Chi eredita l'influenza?
3. **FDA reform**: Kennedy/Trump cambieranno revolving door?
4. **mRNA control**: Chi controlla la piattaforma tecnologica?
5. **Basel concentration**: Antitrust su hub Roche/Novartis?

---

## Fonti

### Istituzioni
- [Gates Foundation](https://www.gatesfoundation.org/)
- [GAVI](https://www.gavi.org/)
- [WHO](https://www.who.int/)
- [CEPI](https://cepi.net/)
- [FDA](https://www.fda.gov/)
- [WEF](https://www.weforum.org/)
- [PhRMA](https://phrma.org/)

### Aziende
- [Pfizer](https://www.pfizer.com/)
- [Eli Lilly](https://www.lilly.com/)
- [J&J](https://www.jnj.com/)
- [Moderna](https://www.modernatx.com/)
- [BioNTech](https://www.biontech.com/)
- [Roche](https://www.roche.com/)
- [Novartis](https://www.novartis.com/)
- [AstraZeneca](https://www.astrazeneca.com/)
- [Merck](https://www.merck.com/)
- [GSK](https://www.gsk.com/)

### Network Accademico
- [Harvard Medical School](https://hms.harvard.edu/)
- [Lilly Endowment](https://lillyendowment.org/)

### Lobbying
- [OpenSecrets - PhRMA](https://www.opensecrets.org/orgs/pharmaceutical-research-manufacturers-of-america/summary)

### Analisi Revolving Door
- [STAT News - Gottlieb Pfizer](https://www.statnews.com/pharmalot/2019/06/27/scott-gottlieb-pfizer-board-fda/)
- [STAT News - Hahn Flagship](https://www.statnews.com/2021/06/15/steve-hahn-fda-moderna-flagship-pioneering/)
- [Stanford Law - FDA Revolving Door](https://law.stanford.edu/publications/fdas-revolving-door-reckoning-and-reform/)
- [NPR - FDA to Industry](https://www.npr.org/sections/health-shots/2016/09/28/495694559/a-look-at-how-the-revolving-door-spins-from-fda-to-industry)

### WEF/Forum
- [WEF Leadership](https://www.weforum.org/about/leadership-and-governance/)
- [Sociable - Andre Hoffmann](https://sociable.co/government-and-policy/who-is-andre-hoffmann-wef-big-pharma-agenda-2030-stakeholder-economy/)

---

*Report creato: Dicembre 2025*
*Ultimo aggiornamento: 4 Febbraio 2025*
*Entità documentate: 10 Pharma, 6 Agency, 2 Foundation, 1 University, 23 org totali*
*Persone con schede complete: 7 (Hoffmann, Gottlieb, Hamburg, Bourla, Bertarelli, Glocer, Warden) + 4 esistenti*
*Persone stub: 18+*
